Literature DB >> 18669163

Aurora-A transcriptional silencing and vincristine treatment show a synergistic effect in human tumor cells.

Laura Lentini1, Angela Amato, Tiziana Schillaci, Lavinia Insalaco, Aldo Di Leonardo.   

Abstract

Aurora-A is a centrosome-associated serine/threonine kinase that is overexpressed in multiple types of human tumors. Primarily, Aurora-A functions in centrosome maturation and mitotic spindle assembly. Overexpression of Aurora-A induces centrosome amplification and G2/M cell cycle progression. Recently, it was observed that overexpression of Aurora-A renders cells resistant to cisplatin (CDDP)-, etoposide-, and paclitaxel-induced apoptosis. Our results indicate that already in initial stages of cancer progression Aurora-A overexpression could have a major role in inducing supernumerary centrosomes and aneuploidy, as shown by immunohistochemistry on tissue sections from various stages of human colon cancer. Aneuploidy was also observed after Aurora-A ectopic overexpression in colon cancer cells with MIN phenotype. Silencing of Aurora-A by RNA interference in tumor cell lines triggered arrest of the cell cycle associated to apoptosis/ mitotic catastrophe. Finally, Aurora-A transcriptional silencing seems to confer cancer cells a greater sensitivity to chemotherapy by vincristine, indicating Aurora-A as a possible gene target in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18669163     DOI: 10.3727/096504008785055521

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  11 in total

1.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

2.  Bioactive tanshinone I inhibits the growth of lung cancer in part via downregulation of Aurora A function.

Authors:  Yanli Li; Yi Gong; Linglin Li; Hamid M Abdolmaleky; Jin-Rong Zhou
Journal:  Mol Carcinog       Date:  2012-03-02       Impact factor: 4.784

3.  Bioactive tanshinones in Salvia miltiorrhiza inhibit the growth of prostate cancer cells in vitro and in mice.

Authors:  Yi Gong; Yanli Li; Yin Lu; Linglin Li; Hamid Abdolmaleky; George L Blackburn; Jin-Rong Zhou
Journal:  Int J Cancer       Date:  2010-11-03       Impact factor: 7.396

4.  Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.

Authors:  Jonathan W Friedberg; Daruka Mahadevan; Erin Cebula; Daniel Persky; Izidore Lossos; Amit B Agarwal; Jungah Jung; Richard Burack; Xiaofei Zhou; E Jane Leonard; Howard Fingert; Hadi Danaee; Steven H Bernstein
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

5.  Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer.

Authors:  Crescent R Isham; Ayoko R Bossou; Vivian Negron; Kelly E Fisher; Rakesh Kumar; Laura Marlow; Wilma L Lingle; Robert C Smallridge; Eric J Sherman; Vera J Suman; John A Copland; Keith C Bible
Journal:  Sci Transl Med       Date:  2013-01-02       Impact factor: 17.956

6.  Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).

Authors:  John M Maris; Christopher L Morton; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Jianrong Wu; Malcolm A Smith; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2010-07-15       Impact factor: 3.167

7.  Tanshinones inhibit the growth of breast cancer cells through epigenetic modification of Aurora A expression and function.

Authors:  Yi Gong; Yanli Li; Hamid M Abdolmaleky; Linglin Li; Jin-Rong Zhou
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

8.  San Huang Decoction Targets Aurora Kinase A to Inhibit Tumor Angiogenesis in Breast Cancer.

Authors:  Yanlei Xu; Cong Wang; Xiyan Chen; Yongfei Li; Weihe Bian; Chang Yao
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279

Review 9.  Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer.

Authors:  Huifeng Niu; Mark Manfredi; Jeffrey A Ecsedy
Journal:  Front Oncol       Date:  2015-08-24       Impact factor: 6.244

10.  Identification of candidate biomarkers correlated with poor prognosis of breast cancer based on bioinformatics analysis.

Authors:  Gang Chen; Mingwei Yu; Jianqiao Cao; Huishan Zhao; Yuanping Dai; Yizi Cong; Guangdong Qiao
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.